Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zasocitinib in Active Psoriatic Arthritis (LATITUDE-PsA-3002)
NCT06671496Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Mar 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of zasocitinib in psoriatic arthritis (PsA) (3 arms), sponsored by Takeda. Primary endpoint: American College of Rheumatology 20 Response at 16 weeks. Started Mar 2025; status: active, not recruiting.
02
Drugs
zasocitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06671496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671496.